Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)
Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.
Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.
The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Gaojun Teng, MD
- Telefonní číslo: +86 13805171500
- E-mail: gjteng@seu.edu.cn
Studijní záloha kontaktů
- Jméno: Binyan Zhong, MD
- Telefonní číslo: +86 15850522044
- E-mail: byzhongir@sina.com
Studijní místa
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510060
- The First Affiliated Hospital, Sun Yat-sen University
-
Kontakt:
- Ming Kuang
- Telefonní číslo: 020-87755766
- E-mail: kuangm@mail.sysu.edu.cn
-
Kontakt:
- Zhenwei Peng
- E-mail: pzhenw@mail.sysu.edu.cn
-
Dílčí vyšetřovatel:
- Wenzhe Fan
-
Guangzhou, Guangdong, Čína, 510317
- Guangdong Second People's Hospital
-
Kontakt:
- Chengjiang Xiao
- Telefonní číslo: +86 13602808387
- E-mail: Xxx196610@163.com
-
Guangzhou, Guangdong, Čína, 510168
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
-
Kontakt:
- Liangliang Qiao
- Telefonní číslo: +86 13544539881
- E-mail: 271937316@qq.com
-
Guangzhou, Guangdong, Čína, 511400
- The Affiliated Panyu Central Hospital of Guangzhou Medical University
-
Kontakt:
- Fuxi Huang
- Telefonní číslo: +86 18902299938
- E-mail: Fuxihuang2006@126.com
-
Guangzhou, Guangdong, Čína, 524003
- The Second Affiliated Hospital of Guangdong Medical University
-
Kontakt:
- Kangshun Zhu
- Telefonní číslo: +86 13602864242
- E-mail: Zhksh010@163.com
-
Jiangmen, Guangdong, Čína, 529030
- Jiangmen Central Hospital
-
Kontakt:
- Yuchuang Liang
- Telefonní číslo: +86 13322888181
- E-mail: jmlyc@21cn.com
-
-
Hubei
-
Wuhan, Hubei, Čína, 430022
- Wuhan Union Hospital of China
-
Kontakt:
- Xuefeng Kan
- Telefonní číslo: +86 13545874189
- E-mail: xkliulang1314@163.com
-
-
Hunan
-
Changsha, Hunan, Čína, 410013
- The Third XIANGYA Hospital of Central South University
-
Kontakt:
- Qi Liang
- Telefonní číslo: +86 137 8731 8180
- E-mail: csuliangqi10@163.com
-
Changsha, Hunan, Čína, 410011
- The Second Xiangya Hospital of Central South University
-
Kontakt:
- Yudong Xiao
- Telefonní číslo: +86 136 3740 3027
- E-mail: xiaoyudong222@csu.edu.cn
-
-
Jiangxi
-
Ganzhou, Jiangxi, Čína, 341000
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University
-
Kontakt:
- Yusheng Song
- Telefonní číslo: +86 135 7675 2988
- E-mail: 646993126@qq.com
-
Nanchang, Jiangxi, Čína, 330209
- The First Affiliated Hospital of Nanchang University
-
Kontakt:
- Junhua Ai
- Telefonní číslo: +86 18170936163
- E-mail: aijh0001@163.com
-
-
Shandong
-
Qingdao, Shandong, Čína, 266000
- The Affiliated Hospital of Qingdao University
-
Kontakt:
- Song Wang
- Telefonní číslo: +86 18661805592
- E-mail: derekqyfy@126.com
-
-
Sichuan
-
Chengdu, Sichuan, Čína, 610041
- West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
-
Kontakt:
- Chang Liu
- Telefonní číslo: +86 18980606382
- E-mail: drliuchang@wchscu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310022
- Zhejiang Cancer Hospital
-
Kontakt:
- Gaojun Teng
- Telefonní číslo: +86 0571 - 88122222
- E-mail: gjteng@seu.edu.cn
-
Kontakt:
- Binyan Zhong
- Telefonní číslo: +86 15850522044
- E-mail: byzhongir@sina.com
-
Dílčí vyšetřovatel:
- Jiaping Zheng
-
Jinhua, Zhejiang, Čína, 321000
- Jinhua Municipal Central Hospital
-
Kontakt:
- Xiaogang Hu
- Telefonní číslo: +86 135 8866 8173
- E-mail: heartdoctor@163.com
-
Lishui, Zhejiang, Čína, 323020
- Lishui Central Hospital
-
Kontakt:
- Jiansong Ji
- Telefonní číslo: +86 0578-2285888
- E-mail: jjstcty@sina.com
-
Kontakt:
- Jianfei Tu
- E-mail: jianfei1133@163.com
-
Ningbo, Zhejiang, Čína, 315010
- Ningbo No.2 Hospital
-
Kontakt:
- Yunjie Chen
- Telefonní číslo: +86 13857877137
- E-mail: a88960317@163.com
-
Ningbo, Zhejiang, Čína, 315048
- Ningbo Medical Center Lihuili Hospital
-
Kontakt:
- Shengdong Wu
- Telefonní číslo: +86 13567886669
- E-mail: 13567886669@139.com
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
- No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
- At least one measurable intrahepatic lesion according to RECIST v1.1.
- ECOG performance status of 0 or 1.
- Child-Pugh class A liver function.
- Life expectancy ≥3 months.
Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥75 × 10⁹/L;
- Hemoglobin ≥90 g/L;
- Serum albumin ≥30 g/L;
- Total bilirubin ≤1.5 × upper limit of normal;
- AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
- TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
- Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.
Exclusion Criteria:
- Diffuse infiltrative liver lesions.
- Contraindications to TACE.
- Allergy to intravenous contrast agent.
- pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
- Patients with HIV or syphilis infection.
- Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
- History of allogeneic organ transplantation.
- Severe dysfunction of the heart, kidney, or other organs.
- Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
- Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg.
TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment.
Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed.
TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
|
|
Aktivní komparátor: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles.
After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall Survival
Časové okno: From randomization to death from any cause, assessed up to approximately 48 months
|
Overall survival is defined as the time from enrollment/randomization to death from any cause.
Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
|
From randomization to death from any cause, assessed up to approximately 48 months
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-Free Survival
Časové okno: From randomization to disease progression or death, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression or death from any cause.
Participants without progression or death will be censored at the last date known to be progression-free.
|
From randomization to disease progression or death, assessed up to approximately 48 months
|
|
Time to Progression
Časové okno: From randomization to disease progression, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression.
Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
|
From randomization to disease progression, assessed up to approximately 48 months
|
|
Objective Response Rate
Časové okno: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Disease Control Rate
Časové okno: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Incidence of Grade ≥3 Adverse Events
Časové okno: From first dose of study treatment through 28 days after the last dose of study treatment
|
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
|
From first dose of study treatment through 28 days after the last dose of study treatment
|
|
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Časové okno: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer.
Scores are linearly transformed to a 0 to 100 scale.
For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning.
For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
|
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Časové okno: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life.
The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity.
Higher scores in each dimension indicate more severe problems or worse health status.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Gaojun Teng, MD, Zhejiang Cancer Hospital
- Vrchní vyšetřovatel: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
- Vrchní vyšetřovatel: Jiansong Ji, MD, The Central Hospital of Lishui City
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary
- Novotvary podle histologického typu
- Novotvary, žlázové a epiteliální
- Adenokarcinom
- Karcinom
- Cholangiokarcinom
- Cirhóza, familiární, s plicní hypertenzí
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Anorganické chemikálie
- Sloučeniny chloru
- Sloučeniny dusíku
- Deoxycytidin
- Cytidin
- Pyrimidinové nukleosidy
- Pyrimidiny
- Platinové sloučeniny
- Gemcitabin
- Cisplatina
- Lenvatinib
- Tislelizumab
Další identifikační čísla studie
Další identifikační čísla studie
- RAINBOW 01
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .